Gigamune, Inc.

Gigamune, Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative gene delivery technologies, particularly using lentiviral vector platforms. The company specializes in advanced gene therapy research and development, with a proprietary technology called "GigaLenti" that enables targeted gene delivery to specific cell types. Registered in the System for Award Management (SAM.gov) since November 2017, Gigamune, Inc. has been actively pursuing federal research grants to advance cutting-edge therapeutic approaches across multiple medical domains.

The company has secured multiple significant federal grants from agencies including the National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Allergy and Infectious Diseases. These grants, ranging from $295,000 to $400,000, have focused on developing innovative gene therapy approaches for complex medical conditions such as Stage IV melanoma, sickle cell disease, Duchenne muscular dystrophy, and autoimmune disorders. Specific research projects have included developing lentiviral vector technologies for in vivo gene delivery to T-cells, creating targeted gene therapies for specific genetic mutations, and exploring novel approaches to cell-specific gene editing. The research consistently emphasizes reducing treatment costs, improving therapeutic efficiency, and creating more accessible treatment modalities for challenging medical conditions, with a particular focus on leveraging the company's proprietary lentiviral vector platform for precise genetic interventions.